News headlines about Bioverativ (NASDAQ:BIVV) have been trending somewhat positive this week, according to Accern. The research group identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Bioverativ earned a coverage optimism score of 0.21 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 45.0906081433178 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the news headlines that may have impacted Accern’s rankings:
- Bioverativ Inc. (BIVV) stands -0.14% away from 50 SMA: Technical Watch – Voice Of Analysts (analystsbuzz.com)
- Morgan Stanley Reiterates “Underweight” Rating for Bioverativ Inc (BIVV) (americanbankingnews.com)
- Stock with lower future earnings – Bioverativ Inc. (BIVV) – Street Observer (press release) (streetobserver.com)
- Attracting Massive Concentrations By Liquidation: Bioverativ Inc. (NASDAQ:BIVV), Molson Coors Brewing (NYSE:TAP) – Investing News Update (investingbizz.com)
- Stochastic Oscillator Analysis for Bioverativ Inc. (NASDAQ:BIVV) – The Oracle Examiner (oracleexaminer.com)
BIVV has been the topic of several research reports. William Blair initiated coverage on Bioverativ in a research note on Wednesday, June 28th. They issued a “market perform” rating on the stock. Cowen and Company upgraded Bioverativ from a “market perform” rating to an “outperform” rating in a research note on Monday, July 10th. Jefferies Group LLC restated a “buy” rating on shares of Bioverativ in a research note on Friday, June 30th. Zacks Investment Research upgraded Bioverativ from a “hold” rating to a “strong-buy” rating and set a $73.00 target price on the stock in a research note on Tuesday, July 25th. Finally, Deutsche Bank AG initiated coverage on Bioverativ in a research note on Friday, June 23rd. They issued a “hold” rating and a $65.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $61.60.
Shares of Bioverativ (BIVV) opened at 58.93 on Friday. Bioverativ has a 52 week low of $41.88 and a 52 week high of $59.29. The stock’s 50 day moving average price is $56.90 and its 200-day moving average price is $56.90. The company has a market cap of $6.38 billion and a PE ratio of 14.41.
Bioverativ (NASDAQ:BIVV) last posted its earnings results on Wednesday, August 2nd. The biotechnology company reported $0.88 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.71 by $0.17. The company had revenue of $289.10 million during the quarter, compared to the consensus estimate of $269.00 million. During the same quarter in the prior year, the business earned $0.59 EPS. The firm’s revenue for the quarter was up 37.5% compared to the same quarter last year. Analysts expect that Bioverativ will post $2.93 EPS for the current year.
In related news, Director Louis J. Paglia bought 2,000 shares of the company’s stock in a transaction dated Monday, August 7th. The shares were bought at an average price of $59.70 per share, for a total transaction of $119,400.00. Following the completion of the acquisition, the director now directly owns 5,056 shares of the company’s stock, valued at $301,843.20. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Brian S. Posner bought 1,000 shares of the company’s stock in a transaction dated Wednesday, August 9th. The stock was bought at an average price of $59.19 per share, for a total transaction of $59,190.00. Following the acquisition, the director now directly owns 6,693 shares of the company’s stock, valued at $396,158.67. The disclosure for this purchase can be found here.
ILLEGAL ACTIVITY NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Bioverativ (BIVV) Share Price” was originally published by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The correct version of this piece of content can be read at https://transcriptdaily.com/2017/10/08/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-bioverativ-bivv-share-price.html.
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Ratings for Bioverativ Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ Inc and related companies with MarketBeat.com's FREE daily email newsletter.